Trombotiske problemer kan udgøre en risiko i denne population, og denne risiko skal omhyggeligt afvejes mod de fordele, behandlingen giver hos denne patientgruppe.
Thrombotic events can be a risk in this population and this possibility should be carefully weighed against the benefit to be derived from the treatment in this patient group.